Trial reportThe Journal of infectious diseases2015
Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects
Clinical Trial to Compare the Immunogenicity of the Inactivated Poliovirus Vaccine (IPV) Administered in Reduced Doses Intramuscularly or Intradermally in Infants at 2 and 4 Months of Age in the Maputo City
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.The Cochrane database of systematic reviews · 2019Pooled it
- Trial
- Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.Human vaccines & immunotherapeutics · 2016Trial
- Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.Human vaccines & immunotherapeutics · 2016Trial
- Article
- Research Progress of Microneedles in Vaccine Delivery.Current medicinal chemistry · 2026Review
- Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020-2022: an, open-label, non-inferiority, randomised, controlled phase 2 trial.EClinicalMedicine · 2025Article
- Population immunity to the three serotypes of poliovirus post-interruption of wild poliovirus transmission in Nigeria.Journal of virus eradication · 2025Article
- A Comprehensive Design-to-skin Pipeline to Fabricate Polymeric Microneedles Using Ultrahigh-resolution 3D Printing.Pharmaceutical research · 2025Article
- Cryomicroneedle Arrays for Biotherapeutics Delivery.Small science · 2025Review
- Review
- Designing a Placebo Microneedle Stamp: Modeling and Validation in a Clinical Control Trial.Pharmaceutics · 2024Article
- Article
- Immune Response of Inactivated Rabies Vaccine Inoculated via Intraperitoneal, Intramuscular, Subcutaneous and Needle-Free Injection Technology-Based Intradermal Routes in Mice.International journal of molecular sciences · 2023Article
- Progress in Intradermal and Transdermal Gene Therapy with Microneedles.Pharmaceutical research · 2022Review
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Antigen Uptake After Intradermal Microinjection Depends on Antigen Nature and Formulation, but Not on Injection Depth.Frontiers in allergy · 2021Article
- The Current Status of Clinical Research Involving Microneedles: A Systematic Review.Pharmaceutics · 2020Review
- Engineering Microneedles for Therapy and Diagnosis: A Survey.Micromachines · 2020Review
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundInactivated polio vaccine (IPV) is necessary for global polio eradication because oral polio vaccine can rarely cause poliomyelitis as it mutates and may fail to provide adequate immunity in immunocompromised populations. However, IPV is unaffordable for many developing countries. Intradermal IPV shows promise as a means to decrease the effective dose and cost of IPV, but prior studies, all using 20% of the standard dose used in intramuscular IPV, resulted in inferior antibody titers.
methodsWe randomly assigned 231 adults with well-controlled human immunodeficiency virus infection at a ratio of 2:2:2:1 to receive 40% of the standard dose of IPV intradermally, 20% of the standard dose intradermally, the full standard dose intramuscularly, or 40% of the standard dose intramuscularly. Intradermal vaccination was done using the NanoPass MicronJet600 microneedle device.
resultsBaseline immunity was 87%, 90%, and 66% against poliovirus serotypes 1, 2, and 3, respectively. After vaccination, antibody titers increased a median of 64-fold. Vaccine response to 40% of the standard dose administered intradermally was comparable to that of the standard dose of IPV administered intramuscularly and resulted in higher (although not significantly) antibody titers. Intradermal administration had higher a incidence of local side effects (redness and itching) but a similar incidence of systemic side effects and was preferred by study participants over intramuscular administration.
conclusionsA 60% reduction in the standard IPV dose without reduction in antibody titers is possible through intradermal administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.